Baird Financial Group, Inc. Revance Therapeutics, Inc. Transaction History

Baird Financial Group, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$11.47 - $25.07 $10,781 - $23,565	940 Added 1.55%	61,586 $706,000
Q2 2023 Aug 11, 2023	SELL	$24.7 - $37.61 $22,896 - $34,864	-927 Reduced 1.51%	60,646 $1.53 Million
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $36,958 - $70,998	2,013 Added 3.38%	61,573 $1.98 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $846,100 - $1.68 Million	59,044 New	59,044 $1.59 Million
Q4 2021 Feb 09, 2022	SELL	$12.46 - $27.87 $604,496 - $1.35 Million	-48,515 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$25.78 - $33.21 $244,600 - $315,096	9,488 Added 24.31%	48,515 $1.35 Million
Q2 2021 Aug 11, 2021	BUY	$26.8 - $31.84 $315,168 - $374,438	11,760 Added 43.13%	39,027 $1.16 Million
Q1 2021 May 13, 2021	BUY	$24.03 - $29.97 $655,226 - $817,191	27,267 New	27,267 $762,000
Q4 2020 Feb 11, 2021	SELL	$23.41 - $28.34 $450,502 - $545,374	-19,244 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$23.23 - $34.3 $81,374 - $120,152	3,503 Added 22.25%	19,244 $484,000
Q2 2020 Oct 22, 2020	BUY	$12.6 - $26.55 $198,336 - $417,923	15,741 New	15,741 $384,000

232

82.1M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Baird Financial Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Baird Financial Group, Inc. with notifications on news.